Epidemiología de la insuficiencia cardíaca aguda

Santiago, Julio Montes; Arévalo-Lorido, José Carlos; González, J.M. Cerqueiro

doi:10.1016/s0025-7753(14)70075-2

Cited by 38 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Spain in accordance with the law, a forensic autopsy is required for all violent deaths and in which there is an unknowned cause of death. This includes sudden and unexpected natural deaths in non-hospitalized persons [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

The ReCaPTa study - a prospective out of hospital cardiac arrest registry including multiple sources of surveillance for the study of sudden cardiac death in the Mediterranean area

Azeli¹,

Barbería²,

Herrera

et al. 2016

Scand J Trauma Resusc Emerg Med

View full text Add to dashboard Cite

BackgroundCardiovascular diseases are one of the leading causes of death in the industrialized world. Sudden cardiac death is very often the first manifestation of the disease and it occurs in the prehospital setting.The determination of the sudden cardiac death phenotype is challenging. It requires prospective studies in the community including multiple sources of case ascertainment that help to identify the cause and circumstances of death.The aim of the Clinical and Pathological Registry of Tarragona (ReCaPTa) is to study incidence and etiology of Sudden Cardiac Death in the Tarragona region (Catalonia, Spain).MethodsReCaPTa is a population-based registry of OHCA using multiple sources of surveillance. The population base is 511,662. This registry is compiled chronologically in a relational database and it prospectively contains data on all the OHCA attended by the EMS from April 2014 to April 2017. ReCaPTa collects data after each emergency medical assistance using an online application including variables of the onset of symptoms. A quality control is performed and it permits monitoring the percentage of cases included by the emergency crew. Simultaneously, data from the medico-legal autopsies is taken from the Pathology Center of the area. All the examination findings following a specific protocol for the sudden death study are entered into the ReCaPTa database by one trained person. Survivors admitted to hospital are followed up and their clinical variables are collected in each hospital. The primary care researchers analyze the digital clinical records in order to obtain medical background. All the available data will be reviewed after an adjudication process with the aim of identifying all cases of sudden cardiac death.DiscussionThere is a lack of population-based registries including multiple source of surveillance in the Mediterranean area. The ReCaPTa study could provide valuable information to prevent sudden cardiac death and develop new strategies to improve its survival.

show abstract

Section: Methodsmentioning

confidence: 99%

The ReCaPTa study - a prospective out of hospital cardiac arrest registry including multiple sources of surveillance for the study of sudden cardiac death in the Mediterranean area

Azeli¹,

Barbería²,

Herrera

et al. 2016

Scand J Trauma Resusc Emerg Med

View full text Add to dashboard Cite

show abstract

“…Las manifestaciones clínicas como la disnea, edema maleolar y fatiga, pueden estar acompañadas por una presión venosa yugular elevada, estertores pulmonares y edemas periféricos con predominancia en miembros inferiores, que afecta la calidad de vida de los pacientes con IC (1) . En un censo realizado en el 2014 se estima que a nivel mundial los casos de IC serían de 23 millones con una incidencia de 5.7 millones de habitantes por año, en Europa (15 millones), Japón (2.4 millones), Australia (0.3 millones), Estados Unidos de América (5.1 millones).…”

Section: Introductionunclassified

“…En un censo realizado en el 2014 se estima que a nivel mundial los casos de IC serían de 23 millones con una incidencia de 5.7 millones de habitantes por año, en Europa (15 millones), Japón (2.4 millones), Australia (0.3 millones), Estados Unidos de América (5.1 millones). La presencia de casos de IC aumenta en 20% para personas mayores de 40 años, aumentando el 1% para personas menores a los 50 años, a los 65 a 70 años en un 5% y en personas mayores de los 80 años aumentaría entre 10 a 20% (1) .…”

Section: Introductionunclassified

Functional capacity, strength and quality of life after a heart failure training program. Randomized clinical trial

Pereira-Rodríguez¹,

Velásquez-Badillo

Peñaranda-Florez³

et al. 2021

Rev. virtual Soc. Parag. Med. Int

View full text Add to dashboard Cite

show abstract

“…[3–6] In addition, such severe disorder has been a major public health problem, and is also associated with high intervention and health care costs, as well as high risk of mortality and morbidity. [7–10] It has been estimated that its prevalence is about 4.2 million in China and 23 million globally. [11–13] Previous studies have reported that patients with senile hypertension (SH) are more likely to suffer from AHF among elderly population.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure

Xie¹,

Ni²,

Zhang³

et al. 2019

Medicine

View full text Add to dashboard Cite

Background:Previous clinical studies have reported that urapidil can effectively treat patients with senile hypertension (SH) and acute heart failure (AHF). However, no studies have systematically assessed the efficacy and safety of urapidil for patients with SH and AHF. Thus, this study will investigate the efficacy and safety of urapidil for SH and AHF.Methods:In this study, we will search the following electronic databases from inception to the June 30, 2019: MEDLINE, EMBASE, Cochrane Library, Google scholar, Springer, WANGFANG, and China Knowledge Resource Integrated Database. We will search all these electronic databases without language limitations. We will also search grey records to avoid missing potential literature. In this study, only randomized controlled trials on assessing efficacy and safety of urapidil for SH and AHF will be considered. We will use RevMan 5.3 software and STATA 15.0 software to carry out statistical analysis.Results:This study will evaluate the efficacy and safety of urapidil for SH and AHF by assessing all-cause mortality, change in body weight, urine output, change in serum sodium; and incidence of all adverse events.Conclusion:This study will provide latest evidence of the efficacy and safety of urapidil for patients with SH and AHF.Dissemination and ethics:This study will only analyze published data; therefore, no ethical approval is needed. The findings of this study will be published at peer-reviewed journals.Systematic review registration:PROSPERO CRD42019139344.

show abstract

Epidemiología de la insuficiencia cardíaca aguda

Cited by 38 publications

References 46 publications

The ReCaPTa study - a prospective out of hospital cardiac arrest registry including multiple sources of surveillance for the study of sudden cardiac death in the Mediterranean area

The ReCaPTa study - a prospective out of hospital cardiac arrest registry including multiple sources of surveillance for the study of sudden cardiac death in the Mediterranean area

Functional capacity, strength and quality of life after a heart failure training program. Randomized clinical trial

Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure

Contact Info

Product

Resources

About